A BILL 
To establish a strategic active pharmaceutical ingredient re-
serve to maintain a domestic supply of active pharma-
ceutical ingredients and key starting materials needed 
for the manufacturing of essential generic medicines, and 
to build a pipeline for domestic active pharmaceutical 
ingredient production. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Promoting Readiness 
4
and Ensuring Proper Active Pharmaceutical Ingredient 
5
22:32 Sep 29, 2021
H5388
2 
•HR 5388 IH
Reserves of Essential Medicines Act of 2021’’ or the 
1
‘‘PREPARE ACT of 2021’’. 
2
SEC. 2. LISTING OF ESSENTIAL GENERIC MEDICINES. 
3
Part B of title III of the Public Health Service Act 
4
(42 U.S.C. 243 et seq.) is amended by inserting after sec-
5
tion 319M the following: 
6
‘‘SEC. 319N. LISTING OF ESSENTIAL GENERIC MEDICINES. 
7
‘‘(a) IN GENERAL.—The Secretary, in consultation 
8
with the Commissioner of Food and Drugs, the Assistant 
9
Secretary for Preparedness and Response, the Secretary 
10
of Defense, Secretary of Homeland Security, and other 
11
heads of agencies, as appropriate, shall establish and make 
12
public a list of essential generic medicines determined, in 
13
accordance with subsection (b), to be medically necessary 
14
to have available at all times. 
15
‘‘(b) REQUIREMENTS.— 
16
‘‘(1) INITIAL LIST.—The initial list of essential 
17
generic medicines under subsection (a) shall be the 
18
generic medicines included on the list of essential 
19
medicines, medical countermeasures, and critical in-
20
puts identified by the Commissioner of Food and 
21
Drugs as published on October 30, 2020, in accord-
22
ance with section 3(c) of Executive Order 13944. 
23
‘‘(c) UPDATES.— 
24
22:32 Sep 29, 2021
H5388
3 
•HR 5388 IH
‘‘(1) ANNUAL
REVIEW.—Not less than once 
1
each year, the Secretary, after consultation with the 
2
Commissioner of Food and Drugs, the Assistant 
3
Secretary for Preparedness and Response, the Sec-
4
retary of Defense, Secretary of Homeland Security, 
5
and other heads of agencies, as appropriate, shall re-
6
view and update the list of essential generic medi-
7
cines required under subsection (a). 
8
‘‘(2) RATIONALE.—In carrying out the annual 
9
review and update under paragraph (1), the Sec-
10
retary shall provide a rationale for each essential ge-
11
neric medicine added to, or removed from, the list 
12
under subsection (a). 
13
‘‘(3) SPECIFIC
14
shall consider including on the list under subsection 
15
(a), and, where appropriate, include on such list, es-
16
sential generic medicines that are essential to spe-
17
cific subpopulations, including pediatric populations, 
18
in developing the list under such subsection. 
19
‘‘(4) THREAT ASSESSMENTS.— 
20
‘‘(A) IN GENERAL.—The Secretary, after 
21
consultation with the Public Health Emergency 
22
Medical Countermeasures Enterprise estab-
23
lished under section 2811–1, shall conduct reg-
24
ular threat assessments, and take such assess-
25
22:32 Sep 29, 2021
H5388
4 
•HR 5388 IH
ments into consideration in updating the list in 
1
accordance with paragraph (1). 
2
‘‘(B) THREAT
ASSESSMENTS
CONSIDER-
3
ATIONS.—Each threat assessment under this 
4
paragraph shall include consideration of— 
5
‘‘(i) the lack of existing domestic ca-
6
pacity of essential generic medicines; 
7
‘‘(ii) the concentration of current sup-
8
ply of the essential generic medicine or ac-
9
tive pharmaceutical ingredients of the es-
10
sential generic medicine in one geo-
11
graphical region; 
12
‘‘(iii) whether there are less than 2 
13
manufacturers of the essential generic 
14
medicine or active pharmaceutical ingredi-
15
ents of the essential generic medicine; and 
16
‘‘(iv) the potential for increased de-
17
mand in a public health emergency. 
18
‘‘(5) DIRECTOR
OF
THE
STRATEGIC
ACTIVE 
19
PHARMACEUTICAL
INGREDIENTS
RESERVE.—The 
20
Secretary shall appoint a Director of the Strategic 
21
Active Pharmaceutical Ingredients Reserve who has 
22
experience in one or more of the following areas: 
23
supply chain management, disaster response, phar-
24
maceutical or active pharmaceutical ingredient devel-
25
22:32 Sep 29, 2021
H5388
5 
•HR 5388 IH
opment, or logistics. Such Director shall ensure a 
1
sufficient supply of the active pharmaceutical ingre-
2
dients and critical components necessary to manu-
3
facture the essential generic medicines included on 
4
the list under subsection (a) in an amount adequate 
5
to serve the needs of patients living in the United 
6
States and in the appropriate dosage forms. 
7
‘‘(d) APPEAL PROCESS.—The Secretary shall estab-
8
lish a process by which stakeholders may appeal a deter-
9
mination by the Secretary not to include an essential ge-
10
neric medicine on the list under subsection (a). 
11
‘‘(e) DEFINITIONS.—In this section: 
12
‘‘(1) DRUG.—The term ‘drug’ has the meaning 
13
given such term in section 201(g) of the Federal 
14
Food, Drug, and Cosmetic Act, and includes a bio-
15
logical product (as defined in section 351(i) of this 
16
Act). Such term includes prescription and non-
17
prescription drugs, or active pharmaceutical ingredi-
18
ents of drugs. 
19
‘‘(2) ESSENTIAL
GENERIC
MEDICINE.—The 
20
term ‘essential generic medicine’ means a drug for 
21
which a generic is approved, that is medically nec-
22
essary to have available at all times because the 
23
drug is— 
24
22:32 Sep 29, 2021
H5388
6 
•HR 5388 IH
‘‘(A) commonly used to prevent, mitigate, 
1
or treat a common disease or condition, or used 
2
in a common procedure; 
3
‘‘(B) an antibiotic or antifungal used to 
4
treat an infectious diseases; 
5
‘‘(C) necessary to prevent or mitigate a 
6
public health emergency; or 
7
‘‘(D) life-supporting, life-sustaining, or in-
8
tended for use in the prevention or treatment of 
9
a debilitating disease or condition.’’. 
10
SEC. 3. ESTABLISHMENT OF THE STRATEGIC ACTIVE PHAR-
11
MACEUTICAL INGREDIENT RESERVE. 
12
Part B of title III of the Public Health Service Act 
13
(42 U.S.C. 243 et seq.), as amended by section 2, is fur-
14
ther amended by inserting after section 319N the fol-
15
lowing: 
16
‘‘SEC. 319N–1. STRATEGIC ACTIVE PHARMACEUTICAL IN-
17
GREDIENT RESERVE. 
18
‘‘(a) STRATEGIC ACTIVE PHARMACEUTICAL INGRE-
19
DIENT RESERVE PLAN.— 
20
‘‘(1) IN
GENERAL.—Not later than 90 days 
21
after the date of enactment of the Promoting Readi-
22
ness and Ensuring Proper Active Pharmaceutical In-
23
gredient Reserves of Essential Medicines Act of 
24
2021, the Secretary, in consultation with the Assist-
25
22:32 Sep 29, 2021
H5388
7 
•HR 5388 IH
ant Secretary for Preparedness and Response, the 
1
Director of the Centers for Disease Control and Pre-
2
vention, the Commissioner of Food and Drugs, and 
3
the Director of the Biomedical Advanced Research 
4
and Development Authority, shall prepare and sub-
5
mit to Congress a Strategic Active Pharmaceutical 
6
Ingredient Reserve Plan (referred to in this section 
7
as the ‘Plan’) in accordance with subsection (b), 
8
which shall be used by the Secretary in establishing 
9
and maintaining the Strategic Active Pharmaceutical 
10
Ingredient Reserve described in subsection (c). 
11
‘‘(2) ANNUAL UPDATES.—The Secretary shall 
12
update the plan annually and, by not later than 
13
June 1 of each year, submit the updated plan to the 
14
applicable committees of Congress. 
15
‘‘(3) NATIONAL SECURITY CONSIDERATIONS.— 
16
‘‘(A) SUBMISSIONS.—The Secretary shall 
17
ensure that any submission of the plan (includ-
18
ing any update to the plan) to the applicable 
19
committees of Congress is in a manner that 
20
does not compromise national security. 
21
‘‘(B) EXEMPTION FROM DISCLOSURE.—In-
22
formation in the plan that, in the judgment of 
23
the Secretary, would reveal public health 
24
vulnerabilities shall be exempt from disclosure 
25
22:32 Sep 29, 2021
H5388
8 
•HR 5388 IH
under section 552(b)(3) of title 5, United 
1
States Code. 
2
‘‘(b) PLAN REQUIREMENTS.— 
3
‘‘(1) IN GENERAL.—The Plan required under 
4
subsection (a) shall— 
5
‘‘(A) detail the design, construction, and 
6
filling of the storage and related facilities com-
7
prising the Strategic Active Pharmaceutical In-
8
gredient Reserve described in subsection (c) (re-
9
ferred to in this section as the ‘Reserve’); 
10
‘‘(B) detail the requirements for maintain-
11
ing the Reserve described in subsection (c), in-
12
cluding— 
13
‘‘(i) storage and testing requirements, 
14
consistent with parts 210 and 211 of title 
15
21, Code of Federal Regulations, or any 
16
successor regulation; and 
17
‘‘(ii) any specific criteria agreed to by 
18
the Secretary and the manufacturer of the 
19
essential generic medicine using the active 
20
pharmaceutical ingredient or key starting 
21
material; 
22
‘‘(C) be designed to minimize the impact of 
23
any interruption or reduction in imports of— 
24
22:32 Sep 29, 2021
H5388
9 
•HR 5388 IH
‘‘(i) active pharmaceutical ingredients 
1
and other key starting materials that the 
2
Secretary determines are, or are likely to 
3
become, dependent upon such imports for 
4
a substantial portion of finished essential 
5
generic medicines; and 
6
‘‘(ii) finished dosage forms of essential 
7
generic medicines for which active pharma-
8
ceutical ingredients and other key starting 
9
materials are not imported; 
10
‘‘(D) include provisions to strengthen do-
11
mestic capacity for active pharmaceutical ingre-
12
dient production, storage, and conversion; and 
13
‘‘(E) outline plans and processes for co-
14
ordinating and consulting, as appropriate, with 
15
the Assistant Secretary for Preparedness and 
16
Response regarding relevant issues of interest 
17
pertaining to the maintenance and stocking of 
18
the strategic national stockpile. 
19
‘‘(2) REQUIRED COMPONENTS.— 
20
‘‘(A) IN GENERAL.—The Plan shall include 
21
the following: 
22
‘‘(i) Identification and prioritization of 
23
the essential generic medicines included on 
24
22:32 Sep 29, 2021
H5388
10 
•HR 5388 IH
the 
most 
recent 
list 
under 
section 
1
319N(a)— 
2
‘‘(I) that the Secretary deter-
3
mines are essential for health care 
4
needs in the United States; and 
5
‘‘(II) for which the Secretary de-
6
termines that there is the greatest 
7
need to maintain a reserve of the ac-
8
tive pharmaceutical ingredients and 
9
key starting materials for the essen-
10
tial generic medicines— 
11
‘‘(aa) taking into account 
12
factors including the extent to 
13
which the United States is, or is 
14
at risk of becoming, dependent 
15
on foreign sources for a substan-
16
tial portion of the domestic need; 
17
and 
18
‘‘(bb) giving special consid-
19
eration to the essential generic 
20
medicines at risk of supply inter-
21
ruption as a result of the factors 
22
described 
in 
section 
23
319N(c)(4)(B). 
24
22:32 Sep 29, 2021
H5388
11 
•HR 5388 IH
‘‘(ii) An evaluation of the utilization 
1
levels of the essential generic medicines 
2
identified under clause (i) to inform how 
3
much of the active pharmaceutical ingredi-
4
ents of such medicines is required to cover 
5
the projected health care needs for one 
6
year of the United States population. 
7
‘‘(iii) A comprehensive assessment of 
8
the essential generic medicines identified 
9
under clause (i), including the existing 
10
manufacturing bases for each such medi-
11
cine (including identification and location 
12
of ownership of such facilities) and wheth-
13
er the active pharmaceutical ingredients of 
14
such ingredients are manufactured domes-
15
tically or abroad, and whether finished dos-
16
age conversion steps for such essential ge-
17
neric medicines are performed domestically 
18
or abroad. 
19
‘‘(iv) The types of facilities, equip-
20
ment, and technology required to appro-
21
priately store, track, test, and convert all 
22
forms of active pharmaceutical ingredients 
23
that are critical inputs of drugs that are 
24
essential generic medicines, preliminary 
25
22:32 Sep 29, 2021
H5388
12 
•HR 5388 IH
proposed locations for such public and pri-
1
vately owned facilities in multiple locations 
2
in the United States, the capacity required 
3
of the facilities used, and the estimated 
4
cost of acquisition and storage of the ac-
5
tive pharmaceutical ingredients and man-
6
agement and operation of the facilities. 
7
‘‘(v) An evaluation of the impact that 
8
the establishment and ongoing mainte-
9
nance of the Reserve may have, including 
10
on availability and pricing of active phar-
11
maceutical ingredients and finished drug 
12
dosages. 
13
‘‘(vi) A distribution plan for the active 
14
pharmaceutical ingredients held in the Re-
15
serve, which shall include— 
16
‘‘(I) protocols for the method of 
17
conversion of active pharmaceutical 
18
ingredients into finished drugs, in-
19
cluding conversion of key starting ma-
20
terials into active pharmaceutical in-
21
gredients and distribution from the 
22
Reserve into the strategic national 
23
stockpile and other government and 
24
22:32 Sep 29, 2021
H5388
13 
•HR 5388 IH
commercial pharmaceutical distribu-
1
tion networks; and 
2
‘‘(II) benchmarks for the Sec-
3
retary to initiate conversion of drug 
4
products that are essential generic 
5
medicines using the active pharma-
6
ceutical ingredients stored in the Re-
7
serve for transfer to the strategic na-
8
tional stockpile or other government 
9
or commercial pharmaceutical dis-
10
tribution networks, based on changes 
11
in the supply chain for the top essen-
12
tial generic medicines or a determina-
13
tion by the Secretary regarding a 
14
threat to public health. 
15
‘‘(vii) A mechanism through which 
16
private sector manufacturers of active 
17
pharmaceutical ingredients or finished dos-
18
age forms may, through contracts with ex-
19
isting Reserve facilities, store and with-
20
draw such ingredients in the Reserve to 
21
enhance resilience and reduce shortages 
22
and disruptions in the supply chain. 
23
‘‘(viii) A mechanism through which 
24
the Federal Government may purchase, via 
25
22:32 Sep 29, 2021
H5388
14 
•HR 5388 IH
manufacturing partners, reserve capacity 
1
for finished drug manufacturing to convert 
2
active pharmaceutical ingredients into fin-
3
ished drugs for essential generic medicines. 
4
‘‘(B) NUMBER OF DRUGS.— 
5
‘‘(i) IN GENERAL.—Pursuant to sub-
6
paragraph (A)(i), the Secretary shall en-
7
sure that for the first year after the date 
8
of enactment of the Promoting Readiness 
9
and Ensuring Proper Active Pharma-
10
ceutical Ingredient Reserves of Essential 
11
Medicines Act of 2021, the Plan includes 
12
not less than 25 essential generic medi-
13
cines, and that 25 additional essential ge-
14
neric medicines are included in such Plan 
15
for each year thereafter until the active 
16
pharmaceutical ingredients necessary to 
17
support the full list of essential generic 
18
medicines identified under section 319N(a) 
19
are covered. 
20
‘‘(ii) PRIORITIZATION.—The Secretary 
21
shall prioritize essential generic medicines 
22
needed immediately in the event of an 
23
emergency. 
24
22:32 Sep 29, 2021
H5388
15 
•HR 5388 IH
‘‘(3) QUANTITIES OF APIS AND KEY STARTING 
1
MATERIALS.— 
2
‘‘(A) IN GENERAL.—To the maximum ex-
3
tent practicable, the Plan should include a plan 
4
to ensure that, for each essential generic medi-
5
cine included in the Plan, the active pharma-
6
ceutical ingredients used in the production of 
7
such medicine that are stored in the Reserve 
8
are available in the minimum quantities as fol-
9
lows: 
10
‘‘(i) By the date that is 18 months 
11
after the date of enactment of the Pro-
12
moting Readiness and Ensuring Proper 
13
Active Pharmaceutical Ingredient Reserves 
14
of Essential Medicines Act of 2021, not 
15
less than 10 percent of the total amount of 
16
such ingredients needed to produce suffi-
17
cient quantities of the essential generic 
18
medicines for the treatment of individuals 
19
living in the United States. 
20
‘‘(ii) By the date that is 3 years after 
21
such date of enactment, not less than 25 
22
percent of the total amount of such ingre-
23
dients needed to produce sufficient quan-
24
tities of the essential generic medicines for 
25
22:32 Sep 29, 2021
H5388
16 
•HR 5388 IH
the treatment of individuals living in the 
1
United States. 
2
‘‘(iii) By the date that is 5 years after 
3
such date of enactment, not less than 50 
4
percent of the total amount of such ingre-
5
dients needed to produce sufficient quan-
6
tities of the essential generic medicines for 
7
the treatment of individuals living in the 
8
United States. 
9
‘‘(iv) By the date that is 10 years 
10
after such date of enactment, not less than 
11
90 percent of the total amount of such in-
12
gredients needed to produce sufficient 
13
quantities of the essential generic medi-
14
cines for the treatment of individuals living 
15
in the United States. 
16
‘‘(B) CALCULATION
OF
QUANTITY
OF 
17
API.—In calculating the quantities of active 
18
pharmaceutical ingredients needed for purposes 
19
of subparagraph (A), the Secretary shall deter-
20
mine the quantity of each essential generic 
21
medicine required to cover the projected health 
22
care needs, over a 1-year period, of people living 
23
in the United States, based on average annual 
24
demand during the 3-year period preceding the 
25
22:32 Sep 29, 2021
H5388
17 
•HR 5388 IH
date of enactment of the Promoting Readiness 
1
and Ensuring Proper Active Pharmaceutical In-
2
gredient Reserves of Essential Medicines Act of 
3
2021. 
4
‘‘(c) ADMINISTERING THE STRATEGIC ACTIVE PHAR-
5
MACEUTICAL INGREDIENT RESERVE.— 
6
‘‘(1) IN GENERAL.—With respect to each active 
7
pharmaceutical ingredient and key starting material 
8
that is included in the Plan, the Secretary shall 
9
place in storage, transport, track, and exchange 
10
quantities of the substance that are— 
11
‘‘(A) produced in conformance with all 
12
quality requirements under this Act and the 
13
Federal Food, Drug, and Cosmetic Act, includ-
14
ing the associated regulations of such Acts; 
15
‘‘(B) stored in compliance with— 
16
‘‘(i) the requirements of parts 210 
17
and 211 of title 21, Code of Federal Regu-
18
lations, or any successor regulation; and 
19
‘‘(C) any specific criteria agreed to by the 
20
Secretary and the manufacturer of the essential 
21
generic medicine using the active pharma-
22
ceutical ingredient or key starting material. 
23
‘‘(2) REQUIREMENTS.—To the greatest extent 
24
practicable, in carrying out paragraph (1), the Sec-
25
22:32 Sep 29, 2021
H5388
18 
•HR 5388 IH
retary shall acquire active pharmaceutical ingredi-
1
ents and key starting materials in a manner that 
2
minimizes cost, minimizes vulnerability of the United 
3
States to severe shortages or disruptions for essen-
4
tial generic medicines, minimizes the impact of ac-
5
quisition of such ingredients and materials to the 
6
marketplace, gives preference to domestic manufac-
7
turers, and encourages competition in the market-
8
place. 
9
‘‘(3) DRAWDOWN OF THE RESERVE.— 
10
‘‘(A) IN
GENERAL.—The Secretary may 
11
distribute active pharmaceutical ingredients and 
12
key starting materials in the Reserve in order 
13
to initiate conversion of active pharmaceutical 
14
ingredients and finished dosage form, in accord-
15
ance with the Plan developed under subsection 
16
(b). 
17
‘‘(B) DEVIATIONS FROM PLAN.—In distrib-
18
uting active pharmaceutical ingredients and key 
19
starting materials under subparagraph (A), the 
20
Secretary, in consultation with the Commis-
21
sioner of Food and Drugs and the Assistant 
22
Secretary for Preparedness and Response, may 
23
deviate from the Plan developed under sub-
24
section (b) only after certifying that the dis-
25
22:32 Sep 29, 2021
H5388
19 
•HR 5388 IH
tribution from the Reserve is required in re-
1
sponse to a significant drug supply interrup-
2
tion. 
3
‘‘(d) CONSULTATION.— 
4
‘‘(1) IN GENERAL.—In carrying out this sec-
5
tion, the Secretary shall consult with— 
6
‘‘(A) the Commissioner of Food and 
7
Drugs, with respect to identifying essential ge-
8
neric medicines; 
9
‘‘(B) the Administrator of the Centers for 
10
Medicare & Medicaid Services, with respect to 
11
determining the volume of essential generic 
12
medicines needed domestically; and 
13
‘‘(C) the Assistant Secretary for Prepared-
14
ness and Response, and, as appropriate, the Di-
15
rector of the Centers for Disease Control and 
16
Prevention, regarding coordination with the 
17
strategic national stockpile. 
18
‘‘(2) REPORTING BY FDA.—The Commissioner 
19
of Food and Drugs shall provide to the Secretary 
20
the information collected under section 510(j)(3) of 
21
the Federal Food, Drug, and Cosmetic Act, for pur-
22
poses of carrying out this section. 
23
‘‘(e) CONTRACTING.— 
24
22:32 Sep 29, 2021
H5388
20 
•HR 5388 IH
‘‘(1) IN GENERAL.—In carrying out this sec-
1
tion, the Secretary shall— 
2
‘‘(A) prioritize the purchase of active phar-
3
maceutical ingredients and other key starting 
4
materials manufactured in the United States by 
5
domestic manufacturers to the maximum extent 
6
possible; 
7
‘‘(B) contract with domestic entities for 
8
the— 
9
‘‘(i) distribution of active pharma-
10
ceutical ingredients and finished drug 
11
products; 
12
‘‘(ii) storage, withdrawal, testing, and 
13
conversion of active pharmaceutical ingre-
14
dients and other key starting materials; 
15
‘‘(iii) tracking and coordinating the 
16
storage, testing, and sale of active pharma-
17
ceutical ingredients and other key starting 
18
materials; 
19
‘‘(iv) sale of active pharmaceutical in-
20
gredients in advance of their expiration 
21
dates; and 
22
‘‘(v) manufacturing, including contin-
23
uous manufacturing as appropriate, of an 
24
active pharmaceutical ingredient or other 
25
22:32 Sep 29, 2021
H5388
21 
•HR 5388 IH
key starting material of an essential ge-
1
neric medicine that is anticipated to be in 
2
shortage, as defined by the Secretary for 
3
purposes of this section; 
4
‘‘(C) give preference to domestic nonprofit 
5
and public-private partnerships, as appropriate; 
6
‘‘(D) ensure geographic diversity of the 
7
physical storage of active pharmaceutical ingre-
8
dients and other key starting materials; 
9
‘‘(E) support domestic manufacturers of 
10
active pharmaceuticals and other key starting 
11
materials and facilitate long-term domestic ca-
12
pacity for essential generic medicines in the 
13
United States; and 
14
‘‘(F) prioritize contracts that facilitate the 
15
conversation of active pharmaceutical ingredi-
16
ents and other key starting materials into fin-
17
ished dosage form. 
18
‘‘(2) RULE
OF
CONSTRUCTION.—Nothing in 
19
this subsection shall be construed to limit the Sec-
20
retary’s ability to enter into other types of contracts 
21
to facilitate the implementation of this section. 
22
‘‘(f) REPORTS TO CONGRESS.—The Secretary shall 
23
report to the applicable committees of Congress on supply 
24
chain resiliency with respect to active pharmaceutical in-
25
22:32 Sep 29, 2021
H5388
22 
•HR 5388 IH
gredients for essential generic medicines, the status of the 
1
Reserve, and other relevant information in a manner that 
2
does not compromise national security. 
3
‘‘(g) DEFINITIONS.—In this section: 
4
‘‘(1) 
APPLICABLE
COMMITTEES
OF
CON-
5
GRESS.—The term ‘applicable committees of Con-
6
gress’ means— 
7
‘‘(A) the Committee on Health, Education, 
8
Labor, and Pensions and the Committee on In-
9
telligence of the Senate; and 
10
‘‘(B) the Committee on Energy and Com-
11
merce of the House of Representatives. 
12
‘‘(2) ESSENTIAL
GENERIC
MEDICINE.—The 
13
term ‘essential generic medicine’ means a drug in-
14
cluded on the most current list under section 
15
319N(a). 
16
‘‘(3) KEY STARTING MATERIAL.—The term ‘key 
17
starting material’ means an active pharmaceutical 
18
ingredient or critical input used in the manufac-
19
turing of an essential generic medicine, as well as in-
20
gredients or components that possess unique at-
21
tributes essential in assessing the safety and effec-
22
tiveness of such essential generic medicines, includ-
23
ing excipients and inactive ingredients. 
24
22:32 Sep 29, 2021
H5388
23 
•HR 5388 IH
‘‘(h) AUTHORIZATION OF APPROPRIATIONS.—There 
1
are authorized to be appropriated to carry out this section 
2
such sums as may be necessary.’’. 
3
SEC. 4. WAIVER OF CERTAIN FDA ANDA REQUIREMENTS. 
4
Section 505(j) of the Federal Food, Drug, and Cos-
5
metic Act (21 U.S.C. 355(j)) is amended by adding at the 
6
end the following: 
7
‘‘(14) Notwithstanding any other provision of 
8
this section, the holder of an approved application 
9
under this subsection that changes the source of an 
10
active pharmaceutical ingredient of the drug that is 
11
the subject of such application to a source available 
12
through the Strategic Active Pharmaceutical Ingre-
13
dient Reserve established under section 319N–1 of 
14
the Public Health Service Act— 
15
‘‘(A) shall not be required to update the 
16
approved application with respect to such 
17
change before changing the source; and 
18
‘‘(B) shall inform the Secretary of the 
19
change, through an update to the approved ap-
20
plication or other manner determined appro-
21
priate by the Secretary, prior to commercial 
22
distribution of the drug.’’. 
23
22:32 Sep 29, 2021
H5388
24 
•HR 5388 IH
SEC. 5. GAO REPORT. 
1
By not later than 18 months after the date of enact-
2
ment of this Act, the Comptroller General of the United 
3
States shall prepare and submit a report to Congress that 
4
includes— 
5
(1) an assessment of what is known about ac-
6
tive pharmaceutical ingredient manufacturing, in-
7
cluding— 
8
(A) the time needed to develop and imple-
9
ment domestic manufacturing capabilities; 
10
(B) projected costs of developing new man-
11
ufacturing capabilities for active pharmaceutical 
12
ingredients not currently available domestically, 
13
as of the date of the report; and 
14
(C) projected costs of expanding existing 
15
domestic capabilities and policies, as of the date 
16
of the report, that may help establish or 
17
strengthen domestic manufacturing capacity for 
18
active pharmaceutical ingredients, excipients, 
19
key starting materials, components, functional 
20
ingredients, and finished dosage manufacturing 
21
facilities; and 
22
(2) an assessment of incentives already offered 
23
or being considered for the development or improve-
24
ment of domestic capacity to manufacture active 
25
22:32 Sep 29, 2021
H5388
25 
•HR 5388 IH
pharmaceutical ingredients, their intermediates, and 
1
their excipients, including— 
2
(A) contractual arrangements for existing 
3
domestic storage and manufacturing of active 
4
pharmaceutical ingredients; 
5
(B) guaranteed contracts for initial pur-
6
chase and replenishment of essential generic 
7
medicines; and 
8
(C) other policies designed to help incentiv-
9
ize the relocation of manufacturing facilities to 
10
the United States or provide economic incen-
11
tives for domestic production. 
12
Æ 
22:32 Sep 29, 2021
H5388
